2022-500347-20-00CompletedPhase 1/2
Safety and Tolerability of AC01 in patients with heart failure
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Mar 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 6 May 2022
- Start date
- 23 Feb 2023
- Lead sponsor
- Anacardio AB
- Diseases
- Heart failure
- EU CT number
- 2022-500347-20-00
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 46
- 10 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (10)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Brescia | Brescia | Italy | Completed |
| Azienda Sanitaria Universitaria Giuliano Isontina | Trieste | Italy | Completed |
| Amsterdam UMC | Amsterdam | Netherlands | Completed |
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
| University Hospital Maastricht | Maastricht | Netherlands | Completed |
| Erasmus MC | Rotterdam | Netherlands | Completed |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Completed |
| Sahlgrenska University Hospital - Vastra Goetalandsregionen | Goteborg | Sweden | Completed |
| Region Skane Skanes Universitetssjukhus | Lund | Sweden | Completed |
| Karolinska University Hospital | Solna | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.